Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
暂无分享,去创建一个
M. Ross | K. Delman | I. Puzanov | M. Milhem | H. Kaufman | J. Zager | F. Collichio | E. Hsueh | L. Cranmer | R. Andtbacka | T. Amatruda | M. Shilkrut | Lisa Chen
[1] M. Burotto,et al. Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Wolchok,et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. , 2015 .
[4] J. Taube,et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. , 2014 .
[5] I. Puzanov,et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. , 2014 .
[6] L. Travaini,et al. Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation. , 2014, Clinical nuclear medicine.
[7] David C. Smith,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Delayed response in ipilimumab therapy. , 2014, The Journal of community and supportive oncology.
[9] S. Kim-Schulze,et al. Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.
[10] K. Harrington,et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[12] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[13] R. Coombes,et al. A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor , 2006, Clinical Cancer Research.
[14] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Coffin,et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.
[16] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.